Posted by Michael Wonder on 04 Mar 2024
NMPA approves the NDA for CARsgen's BCMA CAR-T therapy zevorcabtagene autoleucel for relapsed or refractory multiple myeloma
1 March 2024 - CARsgen Therapeutics announces that today the National Medical Products Administration of China has approved the new drug application for zevorcabtagene autoleucel for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously progressed after at least 3 lines of therapy (including a proteasome inhibitor and immunomodulator agent).
The approval of zevorcabtagene autoleucel is based on an open-label, single arm, multi-centre Phase 2 clinical trial (LUMMICAR) conducted in China.
